Now that Novartis' Tasigna (nilotinib) has been approved by FDA for the treatment of first-line chronic myeloid leukemia, the race has officially begun for two second-generation BCR-ABL kinase inhibitors to supplant the venerable market-leader, Novartis' Gleevec (imatinib). The other competitor expected soon to be vying for a piece of the first-line market is Bristol-Myers Squibb with its Sprycel (dasatinib). That drug, approved since 2006 for second-line CML, has not yet been cleared for first line...